SLCO5A1

Across TCGA pan-cancer cohorts, SLCO5A1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SLCO5A1 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SLCO5A1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLCO5A1 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

LIHC, STAD, and UCS are the cancer types where SLCO5A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.042	0.775	<.001	24	view →
STAD	DFS	Median	III,IV	1.000	0.332	.014	15	view →
UCS	DFS	Median	All	0.126	0.523	.009	6	view →
PRAD	DFS	Median	All	0.534	0.935	.033	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	3	view →
LUAD	DFS	Median	All	0.124	0.357	.019	2	view →
UCEC	DFS	Median	II,III,IV	0.833	0.305	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SLCO5A1–LIHC (OS)

Open the LIHC breakdown →